This Insulet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Several Wall Street analysts have downgraded their ratings for five prominent companies. Insulet Corporation (NASDAQ:PODD) was downgraded from Buy to Hold by Stifel, with a reduced price target. Other downgrades include Bridger Aerospace Group Holdings, Inc. (NASDAQ:BAER) by Canaccord Genuity, The New York Times Company (NYSE:NYT) by Citigroup, Comstock Resources, Inc. (NYSE:CRK) by Morgan Stanley, and Summit Therapeutics Inc. (NASDAQ:SMMT) by Bernstein.
Insulet downgraded by Stifel with a new price target
Stifel has downgraded Insulet (PODD) from a Buy to a Hold rating and set a new price target of $165.00. Historically, after an analyst downgrade, Insulet's stock closed lower four out of five times since January 2026, though past performance is not indicative of future results. The article also provides a brief explanation of what an analyst downgrade signifies.
Should You Continue to Hold Medtronic Stock in Your Portfolio?
Medtronic (MDT) is positioned for growth in its MedSurg and Neuroscience segments, driven by advancements like Hugo adoption, digital surgery, and new product launches, particularly in international markets. However, the company faces headwinds from macroeconomic pressures, product mix shifts, and foreign exchange fluctuations. Despite these challenges, Medtronic has consistently surpassed earnings estimates and maintains a positive outlook for fiscal 2027.
Jefferies Reiterates Buy Rating on Insulet Corporation (PODD)
Jefferies analyst Matthew Taylor has reiterated a Buy rating on Insulet Corporation (NASDAQ: PODD), maintaining a $200.00 price target. The analyst's comments suggest continued confidence in the medical device company. The full article content is only available to premium subscribers.
Stifel downgrades Insulet stock rating on U.S. momentum concerns By Investing.com
Stifel downgraded Insulet Corporation (NASDAQ:PODD) from Buy to Hold and lowered its price target due to concerns about weakening U.S. results and increased competition in the tubeless pump market. The firm anticipates a significant slowdown in Insulet's total year-over-year revenue growth by 2028, with U.S. growth potentially falling to mid-single digits. Despite recent strong third-quarter earnings that surpassed expectations, Stifel believes the competitive landscape will compress the stock's multiple, even though it appears undervalued based on its PEG ratio.
Insulin Delivery Devices Market to Reach US$ 43.11 Billion
The global insulin delivery devices market is projected to grow from US$ 22.04 billion in 2025 to US$ 43.11 billion by 2033, exhibiting an 8.8% CAGR, driven by the increasing prevalence of diabetes and technological advancements. North America leads the market with a 43.50% share, while Asia-Pacific is expected to experience the fastest growth. Key players like Medtronic, Insulet Corporation, and Tandem Diabetes Care are innovating with smart pens, automated insulin delivery systems, and wearable devices to improve diabetes management.
Stifel Downgrades Insulet Corporation (PODD) to Hold
Stifel analyst Jonathan Block downgraded Insulet Corporation (NASDAQ: PODD) from a "Buy" rating to a "Hold." The article notes that this is premium content, requiring a subscription or sign-in to read further details. The downgrade was updated on November 18, 2026, at 3:14 AM EST.
Diabetes Leadership Council and Insulet Corporation Announce Launch of Multiyear Effort to Protect Access to Healthcare for People with Diabetes
The Diabetes Leadership Council (DLC) and Insulet Corporation have launched the Patient Safety Net Protection (PSNP) Collaborative, a multiyear effort to safeguard healthcare access for people with diabetes. This initiative addresses potential health coverage disruptions for over 1 million Americans with diabetes due to anticipated Medicaid cuts and the expiration of Affordable Care Act subsidies. The PSNP Collaborative will assess risks, connect patients to resources, and advocate for policy solutions.
Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration
Senseonics and Beta Bionics have commercially launched the integration of Eversense 365, a year-long implantable continuous glucose monitor, with the iLet Bionic Pancreas for automated insulin delivery. This system autonomously determines insulin doses without requiring carbohydrate counting, aiming to simplify diabetes management. The companies also plan future integration with Beta Bionics' Mint tubeless patch pump to broaden insulin delivery options.
MiniMed and Tandem win FDA clearance for their first tubeless insulin pumps, setting up a 2027 fight with Insulet
MiniMed Group and Tandem Diabetes Care have both received FDA clearance for their first tubeless insulin pumps, setting the stage for a competitive market in 2027 against current leader Insulet. MiniMed Fit, with a seven-day wear time and 300-unit capacity, will launch in spring 2027, while Tandem's tubeless Mobi kit, offering a seven-day infusion set and 200-unit cartridge, is planned for the first half of 2027. Both companies aim to challenge Insulet's Omnipod, which currently dominates the tubeless pump market with a three-day wear time.
MiniMed gets FDA nod for tubeless insulin pump
MiniMed has received FDA clearance for its first tubeless insulin pump, the MiniMed Fit, designed for individuals with Type 1 and Type 2 diabetes aged seven and older. The device can be worn for up to seven days, holds 300 units of insulin, and features a meal detection algorithm. MiniMed aims to compete with Insulet and Tandem Diabetes Care in the patch pump market, with a phased U.S. rollout planned for spring 2027.
Omnipod 5 Wrongful Death Lawsuit Alleges Insulin Pump Overdose Caused Fatal Brain Injury
A Connecticut woman has filed a wrongful death lawsuit against Insulet Corporation, claiming that a defective Omnipod 5 insulin pump led to her relative's fatal brain injury. The lawsuit alleges that the device lacked adequate safety features to prevent dangerously high insulin delivery settings, resulting in severe hypoglycemia, coma, and eventually death for Leslie Ann Silvernail. The complaint highlights Insulet's own warnings about incorrect programming and seeks compensatory damages for negligence.
Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
Tandem Diabetes Care has received FDA clearance for a tubeless version of its miniaturized Mobi automated insulin delivery system, allowing it to be worn on the skin for up to seven days. This new cartridge and infusion set will be launched commercially in the first half of next year through pharmacy channels, providing an extended wear time compared to competitors. The Mobi pump, initially launched in 2024, was designed to be compatible with different wear options, meaning existing users will only need the new accessories.
Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options
Tandem Diabetes Care (NASDAQ:TNDM) has received FDA clearance for its Tandem Mobi insulin pump to offer both tubed and tubeless wear options, making it the first and only system of its kind. The new tubeless cartridge and infusion set will convert existing Mobi pumps and are designed to simplify diabetes management with less frequent site changes, integrating with Control-IQ+ technology. Tandem plans a commercial launch in the U.S. in the first half of 2027, with products exclusively available through pharmacies.
A passive investor reports more than 5% ownership of Insulet (PODD), with shared voting power.
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a passive ownership stake of 6.85% in Insulet Corp (PODD) through a Schedule 13G filing. This represents 4,748,776 common shares, with shared voting power over 4,642,483 shares. The event date for this beneficial ownership was identified as September 30, 2026.
Tandem Diabetes Care gets FDA clearance for tubeless Mobi
Tandem Diabetes Care has received FDA clearance for new tubeless Mobi insulin pump supplies, allowing for up to seven days of wear for its infusion sets. These new supplies are compatible with existing Mobi pumps, with a U.S. commercial launch scheduled for the first half of 2027, initially available through pharmacy benefits. This development provides a competitive edge against rivals like Insulet Corporation's Omnipod, which offers three days of tubeless delivery, though Tandem's insulin cartridge still requires three-day changes.
Sanofi teams with British comic Beano for Type 1 diabetes education push
Sanofi UK is collaborating with the classic British comic Beano and DigiBete to launch free primary school classroom resources aimed at educating children about Type 1 diabetes. This initiative, coinciding with World Diabetes Day, builds on previous partnerships and seeks to foster understanding of the condition, which is often diagnosed in younger children and is not linked to diet or lifestyle. The program uses the familiar Beano characters to help teachers discuss both the biological and emotional aspects of living with Type 1 diabetes in an accessible way.
Did Earnings Beat Just Shift Insulet (PODD) Investment Narrative?
Insulet (PODD) reported strong third-quarter 2026 earnings, including US$842 million in revenue and US$141.1 million in net income, and announced a new US$1.0 billion share repurchase program. The company narrowed its full-year revenue guidance to the high end, emphasizing consistent execution, capital returns, and continued investment in Omnipod adoption and international expansion. While the earnings beat supports the existing growth narrative, the impact of the share repurchase program will depend on the successful execution of its expansion strategies and mitigation of risks like type 2 attrition and recall-related costs.
Insulet (PODD) Could Be 20% Undervalued As Guidance Rises And Buyback Begins
Insulet (PODD) recently announced strong third-quarter earnings, increased full-year revenue guidance, and a new US$1 billion share repurchase plan. Despite a recent stock price bounce, it remains down sharply year-to-date. Analysts view Insulet as undervalued, with a fair value of $178.35 against its current $148.06, driven by its AID opportunity and product roadmap, though risks like weak type 2 retention and litigation exist.
Tandem Diabetes Care, Inc. (TNDM) stock price, news, quote and history
Tandem Diabetes Care, Inc. (TNDM) stock closed at $17.51, down 6.71% on November 12th, 2026. The company, which specializes in technology solutions for diabetes management, has a market cap of $1.222 billion and reported a negative profit margin of -2.50% in Q3 FY26. Analysts currently have an average 1-year target estimate of $26.90 for the stock.
These healthcare stocks have tumbled in 2026, yet Quant ratings stay positive
Several healthcare stocks have experienced significant declines in 2026, with some falling over 40%, despite maintaining Buy or Strong Buy Quant Ratings from Seeking Alpha. The sector faces challenges from regulatory uncertainty and high financing costs, but innovation and demand for advanced treatments offer growth opportunities. The article highlights 10 underperforming healthcare stocks that still hold favorable quantitative assessments.
Insulet Corp. stock rises Monday, still underperforms market
Shares of Insulet Corp. (PODD) advanced 2.25% to $149.81 on Monday, ending a two-day losing streak. Despite the rise, the stock underperformed the broader market, as the S&P 500 Index (SPX) rose 2.35% and the Dow Jones Industrial Average (DJIA) gained 2.15%.
Truist raises Insulet stock price target on Q4 guidance beat
Truist Securities increased its price target for Insulet Corporation (NASDAQ:PODD) to $160 from $153, maintaining a Hold rating. This adjustment follows Insulet's fourth-quarter U.S. guidance beating previous expectations and modest improvements in Type 2 retention rates. Despite some cautious outlooks for 2027 due to new competition and international comparisons, the company recently reported strong Q3 2026 results, exceeding Wall Street's profit and revenue forecasts.
Insulet launches “Give Yourself the Freedom to” campaign, encouraging people with diabetes to prioritize their well-being
Insulet Corporation has launched its "Give Yourself the Freedom to" campaign to highlight the mental and emotional challenges of living with diabetes, coinciding with World Diabetes Day. A global survey commissioned by Insulet found that approximately 6 in 10 people with type 1 and type 2 diabetes desire more holistic support, including mental health resources. The campaign encourages self-care and aims to integrate mental well-being into diabetes management, building on Insulet's existing partnership with Calm for mindfulness tools.
Insulet Corporation (PODD) PT Raised to $160 at Truist Securities
Truist Securities analyst Richard Newitter raised the price target for Insulet Corporation (PODD) to $160. The article, updated on November 9, 2026, reports on this analyst rating change. The full details are available only to premium subscribers.
American Express’s CEO Sold $99 Million of Stock the Day Before the Crash
American Express (AXP) CEO Stephen Squeri sold $99 million of exercised stock options on November 4, 2026, one day before a significant tech-led market selloff that saw the Nasdaq Composite lose $2.5 trillion. While the timing appears problematic, AXP shares traded higher on November 5 than Squeri's average sale price, mitigating the appearance of a perfectly timed exit. This sale is also part of a pattern for Squeri, who made similar large-scale sales in 2022 and 2024.
Midday Pulse: S&P 500 top intraday losers
This article highlights the top intraday losers on the S&P 500 on a recent Friday, despite the overall index rising by 0.9%. Companies experiencing significant declines include Axon Enterprises, Microchip Technology, Insulet Corp., Centene Corp., and Gartner. The report quickly summarizes the stock performance for these companies.
Nasdaq achieves a 1% advance; indexes see big losses for the week
On Friday, Wall Street saw a mixed close, with the Nasdaq Composite rising 1.1% to lead a recovery after its worst day in over a year, while the S&P 500 gained 0.3% and the Dow Jones Industrial Average fell 0.5%. Despite Friday's gains, all major indexes recorded significant losses for the week. Analyst Alex King from Cestrian Capital Research anticipates new all-time highs for equity indices within three months, fueled by a resurgence in the AI trade.
What Is Behind The Move In DexCom Stock?
DexCom (DXCM) stock fell 6.0% on Friday, November 6, 2026, without company-specific news, echoing similar declines in peers Insulet and Tandem Diabetes Care. Tandem's earnings call revealed slower-than-expected pharmacy distribution which could impact 2027 revenue growth, potentially affecting DexCom due to its presence in the same diabetes market. Despite this recent fall, DexCom's shares have returned 34.0% over the past year, significantly outperforming the S&P 500.
Helios Technologies stock hits 52-week low at 49.63 USD
Helios Technologies Inc. (HLIO) stock has fallen to a 52-week low of $49.63, reflecting decreased investor confidence despite the company reporting better-than-expected fiscal third-quarter 2026 results. InvestingPro data suggests the stock may be undervalued with a PEG ratio of 0.27, indicating attractive pricing relative to growth. The company also raised its full-year sales outlook, though it tempered expectations for the pace of growth in 2027.
Tandem Diabetes Care names next CEO
Tandem Diabetes Care has announced Jeannette Bankes as its next CEO, effective November 16, succeeding John Sheridan who will retire at year-end. Bankes joins from GE HealthCare where she was CEO of patient care solutions. Sheridan, who led Tandem since 2019, will remain as a consultant after his retirement, having overseen the launch of key technologies like hybrid closed-loop systems and the development of a tubeless insulin pump.
Pelagos Insurance Capital stock hits all-time high at 28.85 USD
Pelagos Insurance Capital (PLGO) stock reached an all-time high of $28.85, currently trading at $27.97, reflecting a 54% increase over the past year. Despite strong investor confidence and a "GREAT" financial health score from InvestingPro, the stock appears overvalued relative to its Fair Value. The company recently reported second-quarter earnings below expectations, though gross premiums written and book value per diluted share both saw increases.
Axon Enterprise stock hits 52-week low at $334.96
Axon Enterprise Inc.'s stock recently hit a 52-week low of $334.96 and is currently trading at $322.04, reflecting a 10.6% decline in the past week and a 36.51% decline over the past year. The company also reported third-quarter revenue of $908.6 million and adjusted earnings of $1.72 per share, both falling short of Wall Street expectations. Despite these challenges, InvestingPro analysis suggests the stock is currently undervalued.
Vishay Q3 revenue jumps 24% to a record $978.9 million as gross margin widens to 25.5%; Q4 guided to about $990 million
Vishay Intertechnology reported a record Q3 revenue of $978.9 million, a 24% increase year-over-year, surpassing its own guidance, with gross margin expanding to 25.5%. Net earnings reached $59.0 million, reversing a prior-year loss. The company projects Q4 revenue of approximately $990 million and a gross margin of 26.0%.
Insulet Q3 revenue rises 19% to $842 million as it lifts its margin outlook and authorizes a $1 billion buyback
Insulet reported a 19.2% increase in third-quarter revenue, reaching $842.0 million, slightly exceeding its guidance. The company also announced a new $1 billion share repurchase program, with $400 million planned for Q4, and raised its 2026 revenue growth and adjusted operating margin expansion outlook. CEO Ashley McEvoy highlighted strong performance and progress on the company's type 2 action plan and pivotal studies.
Amprius Technologies stock hits 52-week low at 7.26 USD
Amprius Technologies (AMPX) stock has fallen to a 52-week low of $7.26, reflecting a 35% decrease over the past year and over 60% in the last six months. Despite this downturn, InvestingPro analysis suggests the stock is undervalued, presenting a potential opportunity. Recent positive developments include a $75 million grant from the U.S. Department of Defense for EV battery production and several analysts reiterating Buy ratings with price targets significantly above current levels.
Jefferies raises Insulet stock price target to $200 on strong results
Jefferies has increased its price target for Insulet Corporation (NASDAQ:PODD) to $200 from $190, maintaining a Buy rating, following the company's robust third-quarter 2026 results. Insulet reported sales of $842 million, surpassing estimates with 19.6% growth, and earnings per share of $1.99, a 60% increase over consensus. The company also raised its full-year 2026 sales guidance and reiterated strong EPS growth expectations.
Insulet Closes 6.6% Higher After Third-Quarter Revenue Beat Estimates
Insulet (NASDAQ: PODD), the maker of the Omnipod insulin pump, saw its shares close 6.6% higher at $165.02 after reporting third-quarter revenue of $842 million, which surpassed analyst expectations of approximately $832.64 million. This revenue represents a 19.2% increase year-over-year. The company's chief executive expects slower growth and potential market share erosion in 2027.
PODD Q3 2026 deep dive: international strength and innovation pipeline set stage for moderate growth
Insulet Corporation (NASDAQ:PODD) reported strong Q3 2026 results, surpassing Wall Street expectations with revenue up 19.2% year-on-year and non-GAAP profit exceeding estimates by 25.4%. The company's success was attributed to international expansion, operational improvements, and strategic initiatives in type 2 diabetes. Looking ahead, Insulet anticipates moderate growth due to increasing competition and a larger revenue base, but remains focused on innovation with upcoming product launches like Omnipod 6 and a fully closed-loop system for type 2 diabetes.
Key facts: Q3 Growth, Buyback; Omnipod Trials, Filing; 2027 Slowdown
Insulet (PODD) reported strong Q3 2026 results with a 19.2% revenue increase to $842 million and an adjusted EPS of $1.99, leading to an increased 2026 revenue floor and a $1 billion buyback approval. The company is advancing its Omnipod 6 system, with trial enrollment completed and 510(k) application submitted, targeting launches in 2027 and 2028 for different systems. Despite these developments, Insulet anticipates slower growth in 2027 due to rising competition and challenging international comparisons.
Insulet Corporation (PODD) Stock Forecasts
Morningstar Senior Equity Analyst Debbie S. Wang reported on Insulet Corporation's third-quarter earnings, noting few surprises but highlighting looming competition. The report details Insulet's Omnipod system, designed to simplify continuous subcutaneous insulin infusion therapy, and suggests an upgrade for full access to detailed analysis.
Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60% and $1 ...
Insulet Corp (PODD) reported strong Q3 2026 results with revenue up 19.2% to $842 million and adjusted EPS jumping 60% to $1.99. The company's global customer base grew over 20%, exceeding 600,000, and it announced a $1 billion increase in share repurchase authorization. While forecasting continued growth, Insulet anticipates moderation in 2027 due to tougher comparisons and increased competition.
Insulet Corporation (PODD) PT Raised to $200 at Jefferies
Jefferies analyst Matthew Taylor has raised the price target for Insulet Corporation (PODD) to $200 from $190, while maintaining a Buy rating. This adjustment follows Insulet's strong Q3 2026 sales and EPS beat, prompting an increase in sales guidance for FY26 and reiterated EPS growth expectations. Despite trimming longer-term sales estimates, the analyst's confidence in margin and EPS growth led to the modest price target increase.
TD Cowen raises Insulet stock price target to $163 on Omnipod strength
TD Cowen increased its price target for Insulet Corporation (NASDAQ:PODD) to $163 from $144, while maintaining a Hold rating, citing strong third-quarter Omnipod sales outside the U.S. and improved retention rates among U.S. Type 2 diabetes patients. Despite a cautious 2027 growth outlook, Insulet reported adjusted earnings of $1.99 per share and revenue of $842 million, both exceeding Wall Street forecasts, indicating solid financial health. The stock is currently trading at $161.44 and is considered undervalued by InvestingPro analysis, with a Fair Value of $195.90.
Insulet Corporation (PODD) PT Raised to $163 at TD Cowen
TD Cowen analyst Matthew Blackman has increased the price target for Insulet Corporation (NASDAQ: PODD) to $163.00, up from the previous $144.00. This adjustment reflects a positive outlook for the company, though the full details are available only to premium subscribers.
What Insulet (PODD) Said on Its Q3 Earnings Call
Insulet (PODD) reported strong third-quarter revenue of $842 million, up 19.2%, driven by international growth and U.S. performance within guidance. The company saw its global customer base increase by over 20%, with type 2 diabetes patients representing over 40% of U.S. new customer starts, noting GLP-1 medicines as complementary, not competitive. Insulet also updated its 2026 outlook, narrowed its revenue expectations to the upper end of its previous range, and provided a cautious 2027 view due to market conditions and new competition.
Insulet Q3 2026 slides: strong beat, but 2027 outlook tempers gains
Insulet (NASDAQ:PODD) reported strong Q3 2026 earnings, beating Wall Street expectations with adjusted EPS of $1.99 and revenue of $842 million, driven by robust international Omnipod sales. Despite raising full-year 2026 guidance, the company's preliminary 2027 outlook suggests a moderation in growth due to a larger revenue base and competitive pressures, tempering investor enthusiasm. Insulet also authorized a $1 billion share repurchase program, signaling confidence in long-term value creation.
[Insulet Q3 2026 Earnings Call] Insulet Q3 Revenue Jumps 19.2% to $842M, But 2027 Outlook Cut to 'Modestly Below' Mid-Teens on Competition Fears
Insulet Corporation reported strong Q3 2026 results with revenue of $842 million, up 19.2% year-over-year, and adjusted EPS up 60% to $1.99. The company narrowed its full-year 2026 guidance to the top end of its previous range. However, Insulet's preliminary 2027 outlook was conservative, projecting growth "modestly below" mid-teens due to a tougher comparison, Omnipod 6 launch timing, and expected competition, though the company expects to remain a leader in new customer starts.
Insulet (NASDAQ:PODD) posts better-than-expected sales in Q3 2026, stock soars
Insulet Corporation (NASDAQ:PODD) reported strong Q3 2026 results, surpassing revenue expectations with a 19.2% year-on-year increase to $842 million and a non-GAAP profit of $1.99 per share, beating analyst estimates by 25.4%. The company also achieved significant margin expansion and announced a share repurchase, demonstrating confidence in its Omnipod platform. Following the announcement, Insulet's shares surged 5.5%.
LiveOne reduces debt by $8.5 million, cuts JGB balance to $9 million By Investing.com
LiveOne (NASDAQ:LVO) announced it has eliminated $8.5 million in JGB debt, reducing its balance to $9 million. The company expects $1.5 million in annual interest savings and is targeting an additional $2 million to $3 million in expense reductions. LiveOne is also preparing for a B2B partner launch, expanding AI monetization, and exploring strategic alternatives for its subsidiary PodcastOne.